摘要
目的探讨人参多糖辅助GP方案治疗非小细胞肺癌(NSCLC)的临床疗效。方法选择2011年1月-2012年6月于我院收治的NSCLC患者80例,根据收治顺序分为观察组和对照组,每组40例。对照组给予GP化疗方案,即吉西他滨+顺铂;观察组在对照组的基础上加用人参多糖注射液,对两组患者的疗效、毒副反应、生存率等进行比较。结果观察组的总有效率显著优于对照组,差异具有统计学意义(x2=4.511,P<0.05);观察组不良反应中白细胞下降、血小板下降、贫血、胃肠道损伤和脱发的发生率均显著低于对照组,差异具有统计学意义(x2=14.25,12.53,4.604,7.031,4.945,P<0.05);观察组的1年生存率与对照组相比差异无统计学意义(P>0.05)。结论人参多糖辅助GP化疗方案治疗NSCLC疗效显著,毒副作用少,值得临床推广。
Objective To explore the clinical efficacy of ginseng polysaccharides combined GP regimen for treatment of non-small cell lung cancer. Methods 80 cases of patients with non-small cell lung cancer received in our hospital from Jan 2011 to Jun 2012 were divided into observation group and control group according to the treated order, with 40 cases in each group. The control group was received chemotherapy GP （gemcitabine ＋ cisplatin）; the observation group were given ginseng polysaccharide injection based on the control group, the efficacy, toxicity and survival rates in the two groups of patients were compared. Results The total effective rate in observation group was 60%, significantly better than the control group （45%）, the difference was statistically significant （x^2=4.511,P〈0.05）; The incidence of decreased leukopenia, thrombocytopenia, anemia, gastrointestinal damage and alopecia in observation group were significantly lower than the control group, the difference was statistically significant （x^2=14.25,12.53,4.604,7.031,4.945,P〈0.05）; One year survival rate in observation group was 65%, there was no significant difference compared with the control group （55%, P〉0.05）. Conclusion Ginseng polysaccharide combined GP regimen for the treatment of non-small cell lung cancer had significant efficacy and fewer side effects, worthy of promotion.
出处
《湖南中医药大学学报》
CAS
2013年第12期36-37,共2页
Journal of Hunan University of Chinese Medicine
关键词
人参多糖
GP化疗
非小细胞肺癌
Ginseng polysaccharide
GP chemotherapy
Non-small cell lung cancer
